Xenetic Biosciences, Inc.
NASDAQ: XBIOW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James F. Parslow
- Employees
- 4
- Headquarters
- Framingham, United States
- IPO year
- 2019
- Market cap
- $5.6M
- Website
- https://www.xeneticbio.com
Loading XBIOW…
Loading profile data…Frequently asked questions about XBIOW
What does Xenetic Biosciences, Inc. (XBIOW) do?
Xenetic Biosciences, Inc. is a biopharmaceutical enterprise primarily engaged in advancing XCART, a bespoke chimeric antigen receptor T cell (CAR T) platform technology. This innovative system is engineered to specifically target unique tumor neoantigens found in individual patients. The company's broader efforts encompass the creation of variou...
Where does XBIOW trade?
Xenetic Biosciences, Inc. (XBIOW) trades on the NASDAQ Capital Market.
What sector is XBIOW in?
Xenetic Biosciences, Inc. (XBIOW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Xenetic Biosciences, Inc.?
James F. Parslow is the chief executive officer of Xenetic Biosciences, Inc. (XBIOW).
Where is Xenetic Biosciences, Inc. headquartered?
Xenetic Biosciences, Inc. is headquartered in United States.
Does XBIOW pay a dividend?
Xenetic Biosciences, Inc. (XBIOW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did XBIOW go public?
Xenetic Biosciences, Inc. (XBIOW) completed its initial public offering in 2019.